Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment

Myelodysplastic syndromes represent a group of hematological neoplastic diseases caused by defective stem cells causing cytopenia and abnormal hematopoiesis. More than 30% of myelodysplastic syndrome cases develop into acute myeloid leukemia. An analysis of bone marrow samples, peripheral blood smea...

Full description

Saved in:
Bibliographic Details
Main Authors: Fabio Stagno, Giuseppe Mirabile, Patricia Rizzotti, Adele Bottaro, Antonio Pagana, Sebastiano Gangemi, Alessandro Allegra
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/13/4/835
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850144558229225472
author Fabio Stagno
Giuseppe Mirabile
Patricia Rizzotti
Adele Bottaro
Antonio Pagana
Sebastiano Gangemi
Alessandro Allegra
author_facet Fabio Stagno
Giuseppe Mirabile
Patricia Rizzotti
Adele Bottaro
Antonio Pagana
Sebastiano Gangemi
Alessandro Allegra
author_sort Fabio Stagno
collection DOAJ
description Myelodysplastic syndromes represent a group of hematological neoplastic diseases caused by defective stem cells causing cytopenia and abnormal hematopoiesis. More than 30% of myelodysplastic syndrome cases develop into acute myeloid leukemia. An analysis of bone marrow samples, peripheral blood smears, multiparametric flow cytometry data, and clinical patient information is part of the current, time-consuming, and labor-intensive work up for myelodysplastic syndromes. Nowadays, clinical biomedical research has been transformed by the advent of artificial intelligence, specifically machine learning. Artificial intelligence (AI) can improve risk assessment and diagnosis, as well as boost the precision of clinical outcome prediction and illness classification. Algorithms based on artificial intelligence may be potentially helpful in discovering new needs for myelodysplastic syndrome-affected patients, choosing treatment and assessing minimal residual disease. In this review, we seek to identify the primary mechanisms and uses of artificial intelligence in myelodysplastic syndrome, pointing out its advantages and disadvantages while discussing the possible benefits of using AI pipelines in a therapeutic setting.
format Article
id doaj-art-f53dbbc26ecc4baa959cb082a08b491d
institution OA Journals
issn 2227-9059
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-f53dbbc26ecc4baa959cb082a08b491d2025-08-20T02:28:19ZengMDPI AGBiomedicines2227-90592025-03-0113483510.3390/biomedicines13040835Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and TreatmentFabio Stagno0Giuseppe Mirabile1Patricia Rizzotti2Adele Bottaro3Antonio Pagana4Sebastiano Gangemi5Alessandro Allegra6Division of Hematology, AOU Policlinico “G. Martino”, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Via Consolare Valeria 1, 98125 Messina, ItalyDivision of Hematology, AOU Policlinico “G. Martino”, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Via Consolare Valeria 1, 98125 Messina, ItalyDivision of Hematology, AOU Policlinico “G. Martino”, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Via Consolare Valeria 1, 98125 Messina, ItalyDivision of Hematology, AOU Policlinico “G. Martino”, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Via Consolare Valeria 1, 98125 Messina, ItalyDivision of Hematology, AOU Policlinico “G. Martino”, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Via Consolare Valeria 1, 98125 Messina, ItalyAllergy and Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125 Messina, ItalyDivision of Hematology, AOU Policlinico “G. Martino”, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Via Consolare Valeria 1, 98125 Messina, ItalyMyelodysplastic syndromes represent a group of hematological neoplastic diseases caused by defective stem cells causing cytopenia and abnormal hematopoiesis. More than 30% of myelodysplastic syndrome cases develop into acute myeloid leukemia. An analysis of bone marrow samples, peripheral blood smears, multiparametric flow cytometry data, and clinical patient information is part of the current, time-consuming, and labor-intensive work up for myelodysplastic syndromes. Nowadays, clinical biomedical research has been transformed by the advent of artificial intelligence, specifically machine learning. Artificial intelligence (AI) can improve risk assessment and diagnosis, as well as boost the precision of clinical outcome prediction and illness classification. Algorithms based on artificial intelligence may be potentially helpful in discovering new needs for myelodysplastic syndrome-affected patients, choosing treatment and assessing minimal residual disease. In this review, we seek to identify the primary mechanisms and uses of artificial intelligence in myelodysplastic syndrome, pointing out its advantages and disadvantages while discussing the possible benefits of using AI pipelines in a therapeutic setting.https://www.mdpi.com/2227-9059/13/4/835artificial intelligencemachine learningmyelodysplastic syndromesMDSdiagnosisflow cytometry
spellingShingle Fabio Stagno
Giuseppe Mirabile
Patricia Rizzotti
Adele Bottaro
Antonio Pagana
Sebastiano Gangemi
Alessandro Allegra
Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment
Biomedicines
artificial intelligence
machine learning
myelodysplastic syndromes
MDS
diagnosis
flow cytometry
title Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment
title_full Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment
title_fullStr Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment
title_full_unstemmed Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment
title_short Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment
title_sort using artificial intelligence to enhance myelodysplastic syndrome diagnosis prognosis and treatment
topic artificial intelligence
machine learning
myelodysplastic syndromes
MDS
diagnosis
flow cytometry
url https://www.mdpi.com/2227-9059/13/4/835
work_keys_str_mv AT fabiostagno usingartificialintelligencetoenhancemyelodysplasticsyndromediagnosisprognosisandtreatment
AT giuseppemirabile usingartificialintelligencetoenhancemyelodysplasticsyndromediagnosisprognosisandtreatment
AT patriciarizzotti usingartificialintelligencetoenhancemyelodysplasticsyndromediagnosisprognosisandtreatment
AT adelebottaro usingartificialintelligencetoenhancemyelodysplasticsyndromediagnosisprognosisandtreatment
AT antoniopagana usingartificialintelligencetoenhancemyelodysplasticsyndromediagnosisprognosisandtreatment
AT sebastianogangemi usingartificialintelligencetoenhancemyelodysplasticsyndromediagnosisprognosisandtreatment
AT alessandroallegra usingartificialintelligencetoenhancemyelodysplasticsyndromediagnosisprognosisandtreatment